SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting
- Findings on the mechanism of action from the BOXR CAR-T platform indicate improved metabolic function and preservation of early memory subsets of T cells.
- SOTIO anticipates initiating first-in-human DUET-01 trial for lead CAR-T cell therapy candidate, BOXR1030, in coming months.
- Phase 2 AURELIO-04 combination study of SOT101 and KEYTRUDA® is enrolling patients across multiple solid tumor indications.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, presented preclinical data evaluating the mechanism of action and metabolic function of its BOXR T cell platform in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022. An additional poster was presented on the trial design of AURELIO-04, an ongoing Phase 2 study evaluating the efficacy and safety of SOT101 in combination with pembrolizumab in patients with advanced solid tumors.
SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster presentations, namely the Phase 2 AURELIO-04 study design of the IL-15 superagonist, SOT101 as a Trial in Progress and nonclinical data on mechanism of action of its BOXR T cell platform, at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.
SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer. Martin Steegmaier brings over 20 years of experience in oncology drug discovery, drug development and business development. His extensive knowledge of the biotech industry and clinical immuno-oncology will be crucial as SOTIO continues to advance multiple assets through the clinic. He will be responsible for preclinical and translational research globally.
SOTIO Biotech B.V.
Strawinskylaan 933
1077XX Amsterdam
Netherlands
Strawinskylaan 933
1077XX Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
Term of use
Data protection
Cookies Policy
Cookie settings
Clinical Trials Privacy Notice
© 2013 - 2024 Sotio
Sitemap
Terms of Use and Privacy
© 2013 - 2024 Sotio